Jeffrey Crawford, MD
Chief, Division of Medical Oncology
Department / Division
Medicine /
Medicine - Oncology
Address
DUMC 3476
Durham, NC 27710
Appointment Telephone
919-668-6688
Office Telephone
919-681-9509
Fax Telephone
919-681-5864
- MD, Ohio State University College of Medicine, 1974
- Internal Medicine, Duke University Medical Center, 1974-1977
- Hematology-Oncology, Duke University Medical Center, 1977-1978, 1979-1981
- Medicine, Chief Resident, Duke University Medical Center, 1978-1979
Clinical Interests
Lung cancer (small-cell and non-small-cell), chemotherapy, hematopoietic growth factors, cancer clinical trials
Research Interests
1. Lung cancer/new treatment approaches.
2. Clinical trials of hematopoietic growth factors, biological agents and targeted drug development.
3. Cancer in the elderly and supportive care
Accomplishments
1. Lead Investigator of the U. S. multicenter, randomized trial of Filgrastim (G-CSF, Neupogen) to reduce the morbidity of chemotherapy-related neutropenia, leading to FDA approval 2/91.
2. Lead Investigator of the U. S. multicenter, randomized trial of Vinorelbine (Navelbine) in treatment of patients with advanced non small cell carcinoma of lung (NSCLC), leading to FDA approval 12/94.
3. Principal Investigator in initial phase I clinical trials of stem cell factor (SCF), megakaryocyte growth and development factor (MGDF), pegylated granulocyte-colony-stimulating factor and other novel hematopoietic growth factors.
This faculty member (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- Amgen, Inc.
- Hoffman LaRoche (Roche Holding)
